相关实验视频
Updated: Sep 18, 2025

10:34
A High-content Assay for Monitoring AMPA Receptor Trafficking
Published on: January 28, 2019
7.8K
神经功能障碍,炎症障碍和代谢干扰是阿曼塔丁相关不良药物事件的特征:FAERS和网络毒理学的观点
Jing Yang1, Yang Tian2, Yue Luo1
1Department of Pharmacy, Mianzhu City People's Hospital, West China Hospital of Sichuan University, Mianzhu, China.
Expert opinion on drug safety
|June 23, 2025
概括
对帕金森病的阿曼塔丁使用与许多不良药物事件 (ADEs) 有关,其中一些不列在药物标签上. 网络毒理学揭示了关键的分子标和参与这些阿曼塔丁副作用的途径.
科学领域:
- 药理学 药理学是指药理学的学科.
- 毒理学 毒理学 毒理学
- 计算生物学 计算生物学
背景情况:
- 阿曼塔丁越来越多地用于帕金森病和帕金森症.
- 与阿曼塔丁相关的不良药物事件 (ADEs) 正在增加.
- 目前尚不清楚阿曼塔丁诱导的ADEs背后的机制.
研究的目的:
- 使用网络毒理学分析阿曼塔丁相关的ADEs.
- 为了确定阿曼塔丁的潜在毒理机制.
主要方法:
- 在FAERS数据库中进行数据挖掘.
- 网络毒理学原则的应用.
- 分子对接模拟. 分子对接模拟.
主要成果:
- 确定了1,917个与阿曼塔丁相关的ADE报告,其中有1,871个显著信号.
- 在目前的阿曼塔丁药物插件中发现了69个未申报的ADEs.
- 发现关键的分子标 (STAT3,MAPK1,CYP3A4) 和途径 (神经活性联体受体相互作用,托尔类受体信号传递) 与阿曼塔丁毒性有关.
- 分子对接证实了阿曼塔丁与神经功能,炎症和新陈代谢相关的蛋白质的高亲密结合.
结论:
- 这项研究为与阿曼塔丁相关的ADEs的机制提供了新的见解.
- 这些发现增强了阿曼塔丁的药监策略.
- 已识别的分子标为预测和减轻阿曼塔丁毒性提供了潜力.
相关概念视频
Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
Drugs Affecting Neurotransmitter Release or Uptake
1.2K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.2K
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Parkinson's Disease: Treatment
391
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
391
Drugs Acting on Autonomic Ganglia: Stimulants
1.5K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.5K
Pharmacovigilance
1.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.0K

